Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InnoCan Pharma ( (TSE:INNO) ) just unveiled an announcement.
Innocan Pharma has partnered with Freedom Farm to provide its LPT-CBD injections for animals suffering from chronic pain, significantly improving their quality of life. This collaboration highlights Innocan’s commitment to compassionate care and the potential of its technology to transform pain management in animals and humans, as demonstrated by the successful treatment of two goats at the sanctuary.
The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$12.00 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.
Spark’s Take on TSE:INNO Stock
According to Spark, TipRanks’ AI Analyst, TSE:INNO is a Neutral.
InnoCan Pharma’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and cash flow issues. The technical analysis suggests bearish momentum, further weighing on the score. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield, contributing to the low overall score.
To see Spark’s full report on TSE:INNO stock, click here.
More about InnoCan Pharma
Innocan Pharma is an innovator in the pharmaceuticals and wellness sectors, focusing on a CBD-loaded liposome drug delivery platform for non-opioid pain management and a wide range of self-care and beauty products. The company emphasizes advanced online sales through its BI Sky Global Ltd. subsidiary.
Average Trading Volume: 1,256
Technical Sentiment Signal: Sell
Current Market Cap: C$45.44M
Learn more about INNO stock on TipRanks’ Stock Analysis page.